SHANTON

Developing novel treatments for gout, hyperuricemia, and pruritus

Founded 2016 · $31.2M raised

Founded
2016
Total Funding
$31.2M
Last Round
$31.2M Series ADec 2020
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Shanton Pharma is a clinical-stage biotech company founded in 2016, focused on the unmet needs associated with gout, hyperuricemia, and pruritus. The company's mission is to develop novel treatments that address global clinical gaps in these inflammatory and metabolic disease areas, with an ultimate goal of completely eliminating gout. Shanton's pipeline includes SAP-001, which has received FDA Fast Track Designation for refractory gout and has completed an End-of-Phase 2 meeting with the US FDA. The company brings together experienced management with relevant drug development track records and is backed by a group of institutional investors focused on biotech.

Summary

SHANTON is a Biotech company, founded in 2016. It has raised $31.2M in total across 1 round, most recently a $31.2M Series A round in Dec 2020. Investors include BioTrack Capital, Cenova Capital and Lapam Capital.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries ADec 2020
$31.2M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SHANTON on Indexed.vc
<a href="https://indexed.vc/companies/shanton"><img src="https://indexed.vc/api/badge/company/shanton" alt="SHANTON on Indexed.vc" width="260" height="76" /></a>